<DOC>
	<DOCNO>NCT01219621</DOCNO>
	<brief_summary>1 Purpose In patient sinus node dysfunction ( SND ) , use AAI mode rare . In paroxysmal high-degree complete atrio-ventricular ( AV ) block , paroxysmal vagally-mediated bradycardia , single chamber atrial pacemaker contraindicate although ventricular support rarely need . As result , patient usually expose unnecessary high proportion ventricular pace due programming system DDD mode preventive safety reason . This drain pulse generator battery , importantly long-term adverse effect ventricular function subset vulnerable patient , lead leave ventricular ( LV ) asynchrony , mitral regurgitation increase left atrium ( LA ) size . The deleterious effect right ventricular ( RV ) pacing , increase heart failure ( HF ) morbidity/mortality , atrial fibrillation ( AF ) relate adverse event highlight several large clinical study . Limiting RV pace non-dependant patient therefore desirable . The Symphony DR 2550 cardiac pacemaker ( SORIN Group , Montrouge , France ) offer new pace mode automatically switch AAI ( R ) mode DDD ( R ) DDI ( R ) event severe atrioventricular conduction disorder , return spontaneously AAI ( R ) mode soon spontaneous AV conduction resume . This particular mode call AAIsafeR2 ( R ) . The objective study three-fold : demonstrate AAIsafeR2 mode ( ) reduce percentage ventricular pacing patient spontaneous AV conduction ( ii ) prevent atrial arrhythmia improve atrial hemodynamics ( iii ) improve long-term hemodynamic status implant patient comparison `` standard '' DDD mode , set long AV Delays ( DDD Long AVD ) . The scientific soundness lie study proposal optimal program dual-chamber pacemaker ( PM ) regard preservation spontaneous AV conduction .</brief_summary>
	<brief_title>Comparison AAIsafeR DDD Modes Non-selected Patients</brief_title>
	<detailed_description>In patient sinus node dysfunction ( SND ) , use AAI mode rare . In paroxysmal high-degree complete atrio-ventricular ( AV ) block , paroxysmal vagally-mediated bradycardia , single chamber atrial pacemaker contraindicate although ventricular support rarely need . As result , patient usually expose unnecessary high proportion ventricular pace due programming system DDD mode preventive safety reason . This drain pulse generator battery , importantly long-term adverse effect ventricular function subset vulnerable patient , lead leave ventricular ( LV ) asynchrony , mitral regurgitation increase left atrium ( LA ) size . The deleterious effect right ventricular ( RV ) pacing , increase heart failure ( HF ) morbidity/mortality , atrial fibrillation ( AF ) relate adverse event highlight several large clinical study . Limiting RV pace non-dependant patient therefore desirable . The Symphony DR 2550 cardiac pacemaker ( SORIN Group , Montrouge , France ) offer new pace mode automatically switch AAI ( R ) mode DDD ( R ) DDI ( R ) event severe atrioventricular conduction disorder , return spontaneously AAI ( R ) mode soon spontaneous AV conduction resume . This particular mode call AAIsafeR2 ( R ) . The objective study three-fold : demonstrate AAIsafeR2 mode ( ) reduce percentage ventricular pacing patient spontaneous AV conduction ( ii ) prevent atrial arrhythmia improve atrial hemodynamics ( iii ) improve long-term hemodynamic status implant patient comparison `` standard '' DDD mode , set long AV Delays ( DDD Long AVD ) . The scientific soundness lie study proposal optimal program dual-chamber pacemaker ( PM ) regard preservation spontaneous AV conduction . 2 Study device Classification Name Manufacturer Name Cardiovascular permanent pacemaker pulse generator SORIN Group Symphony â„¢ DR2550 3 Summary study objectives The aim study assess clinical benefit result AAIsafeR2 comparison standard dual chamber programming ( DDD ) long AV Delay . The benefit assess compare percentage ventricular pacing , incidence atrial arrhythmia , evolution hemodynamic status observe echo parameter ANP/BNP measurement . The primary objective study : demonstrate effectiveness AAIsafeR2 preserve natural AV conduction compare DDD Long AVD . For purpose , ventricular pace ratio retrieve PM memory assess mid-term period ( 1 year ) inter-groups comparison : - Mean V pacing ( % ) - Proportion patient V pace ratio &lt; 1 % . demonstrate effectiveness AAIsafeR2 reduce AF incidence long-term basis ( 3-year follow-up ) analyze randomize branch : - cumulative time AF ( document PM memory ) - total number AF episode ( document PM memory ) - number patient present cumulative time AF &gt; 30 % follow-up period ( documented PM memory ) - proportion patient turn persistent AF study . - proportion patient turn permanent AF study . compare effect AAISafeR2 vs. DDD Long AVD LV function , mitral regurgitation LA dimension long-term basis ( 3-year follow-up ) comparing : - LV ejection fraction ( EF ) volumes - Left atrium dimension - Mitral regurgitation severity measure standard echocardiographic method . The secondary objective study report compare follow randomized arm study : Total mortality CHF-related mortality hospitalization Evolution systemic blood pressure , estimate ANP/BNP measurement AF-related adverse event , strokes/TIA 's cardioversions The evolution cardiac asynchrony [ inter-ventricular ( RV-LV ) intra-ventricular ( 4 segment ) , assess TDI technics ] The evolution conduction disturbances patient present unknown estimate atrio-ventricular block long-term basis ( intra-group analysis ) . Stratification pace indication cardiopathy .</detailed_description>
	<criteria>Inclusion criterion / Indications Any patient fulfil one official guideline implant dualchamber pacemaker ( primoimplantation ) may include study . Exclusion criterion / Contraindications The patient present one follow characteristic include : Permanent complete AV block Permanent atrial and/or ventricular arrhythmia already implant cardioverterdefibrillator ( ICD ) Likely cardiac surgery next six month , mainly : severe coronary artery disease severe valvular disease Refuses sign consent form receive appropriate information Refuses cooperate Not able understand study objective protocol Not available schedule followup With life expectancy le one year Already include another clinical study compete objective CANSAVE R study . &lt; 18 year old . Contraindications Any patient contraindication device label applies shall include study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>Symphony DR 2550 ,</keyword>
	<keyword>Dual Chamber Pacemaker ,</keyword>
	<keyword>Sorin ,</keyword>
	<keyword>Ela Medical ,</keyword>
	<keyword>DDD Mode ,</keyword>
	<keyword>AAIsafeR2 mode ,</keyword>
	<keyword>AV-Conduction ,</keyword>
	<keyword>Reducing Ventricular Pacing ,</keyword>
	<keyword>Congestive Heart Failure ,</keyword>
	<keyword>Cardiac Function ,</keyword>
	<keyword>Atrial Arrhythmia ,</keyword>
	<keyword>Atrial Fibrillation ,</keyword>
	<keyword>Atrial Ventricular Hemodynamics ,</keyword>
	<keyword>Long AV-delays .</keyword>
	<keyword>Ventricular Function ,</keyword>
	<keyword>Implantation ,</keyword>
</DOC>